AI-Driven Demand Fuels Thermo Fisher's Earnings Beat and Raised Outlook

Thermo Fisher Scientific, a Waltham, Massachusetts-based life sciences instrument and equipment maker, reported second-quarter 2026 adjusted earnings of $6.03 per share on revenue of $11.99 billion, beating analyst estimates of $5.72 per share and $11.71 billion in sales. Shares rose 8.97% in early trading.

The company raised its full-year guidance, pointing to broad-based demand that included its newest AI-enabled instruments and software.

Marc Casper, Chairman and CEO of Thermo Fisher Scientific, says customer activity strengthened across every end market the company serves. "Customer activity across our end markets continued to strengthen," Casper says.

Pharma and biotech, the company's largest end market at about 60% of revenue, delivered mid-single-digit growth for the quarter.

AI Tools Headline a Wave of Product Launches

Casper credited the quarter's growth to new products rather than market conditions alone. "Innovation is the most important driver," Casper says.

At the American Society for Mass Spectrometry conference in June, the company launched its Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, both built with AI-driven capabilities aimed at drug development research.

The company also expanded its suite of AI-powered software, which it says delivers smarter lab workflows and speeds up proteomics research.

Casper says Thermo Fisher is deploying AI across its own operations too, using it to accelerate its internal PPI Business System. That system spans manufacturing and productivity efforts across the company.

Pharma's AI Spending Is Filling Thermo Fisher's Order Book

The demand for Thermo Fisher's tools is tied to a broader wave of pharmaceutical investment in AI-based drug discovery. Casper says his conversations with pharma executives increasingly center on artificial intelligence.

"There's a lot of excitement about their pipelines," Casper says, describing those discussions as focused on using AI to accelerate innovation and improve productivity.

That spending has shown up across the industry this year. Eli Lilly expanded its AI drug discovery partnership with Insilico Medicine to $2.75 billion in June, using Insilico's Pharma.AI platform to identify and evaluate new drug candidates, according to coverage of the deal.

Merck signed a deal worth up to $510 million in milestone payments with Protillion Biosciences in June to generate the biological data needed to train its AI drug discovery models, addressing what has become a key bottleneck for the industry.

Analysts expect 15 to 20 AI-designed drug programs to enter pivotal Phase III trials this year, a milestone that could shape how much further pharma companies commit to AI research budgets, according to a look at the year ahead for AI drug discovery.

Those research budgets fund the instruments, reagents and clinical data services that make up Thermo Fisher's core business.

The Financials Behind the Quarter

Thermo Fisher's revenue grew 10% year over year, with organic growth of 5%, two percentage points above its own guidance. Adjusted operating margin expanded to 22.8% from 21.9% a year earlier.

The company's four business segments, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services, all posted higher operating income.

The company raised its full-year revenue guidance to a range of $47.4 billion to $48.1 billion and its adjusted earnings per share guidance to $24.93 to $25.33. It closed its acquisition of clinical data company Clario in March and agreed in April to divest its microbiology business, a deal expected to close in the third quarter.

Thermo Fisher returned $1.2 billion to shareholders in the quarter through buybacks and dividends.

Thermo Fisher's beat follows a similar report from competitor Danaher Corporation, which also posted second-quarter results this week. Danaher reported revenue of $6.3 billion, up 5.5% year over year, and non-GAAP adjusted earnings per share of $1.94, up 8.0%, according to Danaher's second-quarter earnings release.

Danaher's AI investment reaches beyond the lab bench. The company closed its acquisition of Masimo Corporation in June, adding "advanced sensor technology and AI-enabled patient monitoring" to its diagnostics portfolio, according to Danaher's announcement of the deal.

Not every market has recovered evenly, though: China's business grew in the low single digits, and academic and government spending there remained muted, Casper says.

"We're encouraged by it, but we'd like to see the activity continue to be more broad-based before we say that that one's behind us," Casper says. "I feel good about the slow stabilization of that end market."